网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
阿帕替尼对EGFR野生型晚期非小细胞肺癌的疗效分析
作者:刘克  施险峰  汪超  肖鑫 
单位:安徽医科大学附属巢湖医院 肿瘤内科, 安徽 巢湖 238000
关键词:阿帕替尼 晚期非小细胞肺癌 表皮生长因子受体 
分类号:R734.2
出版年·卷·期(页码):2020·39·第七期(859-862)
摘要:

目的:探索阿帕替尼单药治疗表皮生长因子受体(EGFR)阴性的晚期非小细胞肺癌(NSCLC)的有效性和安全性。方法:回顾性分析安徽医科大学附属巢湖医院的62例EGFR阴性的NSCLC患者临床资料,患者均给予阿帕替尼单药治疗,分析其疗效及不良反应发生情况。结果:本研究中75.8%为三线治疗,单药治疗的客观缓解率为8.1%,疾病控制率为56.5%,患者中位无进展生存期为3.46个月。阿帕替尼主要不良反应包括贫血、白细胞下降、血小板下降、出血、高血压、蛋白尿、手足综合征、口腔黏膜炎、乏力,均可耐受。结论:单药阿帕替尼治疗可使EGFR阴性的晚期NSCLC患者获益。

参考文献:

[1] KRIS M G,GASPARL E,CHAFT J E,et al.Adjuvant systemic therapy and adjuvant radiation therapy for stage Ⅰ to ⅢA completely resected non-small-cell lung cancers:American society of clinical oncology/cancer care ontario clinical practice guideline update[J].J Clin Oncol,2017,35(25):2960-2974.
[2] MASTERS G A,TEMIN S,AZZOLI C G,et al,Systemic therapy for stage Ⅳ non-small-cell lung cancer:American society of clinical oncology clinical practice guideline update[J].J Clin Oncol,2015,33(30):3488-3515.
[3] 于舒飞,王燕.甲磺酸阿帕替尼治疗晚期非小细胞肺癌疗效分析[J].癌症进展,2012(6):605-611.
[4] 毕金玲,刘海源,黄勇.阿帕替尼单药治疗进展期非小细胞肺癌疗效观察[J].临床肺科杂志,2017(8):1474-1476.
[5] 王琳,冯久桓,秦叔逵.甲磺酸阿帕替尼的研究现状与进展[J].临床肿瘤学杂志,2017(4):345-356.
[6] SUN J M,AHN M J, PARK M J,et al.Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors[J].Lung Cancer,2010,69(1):105-109.
[7] LAKSHMAN A,MODI M,PRAKASH G,et al.Evaluation of bortezomib-induced neuropathy using total neuropathy score (reduced and clinical versions) and NCI CTCAE v4.0 in newly diagnosed patients with multiple myeloma receiving bortezomib-based induction[J].Clin Lymphoma Myelom,2017,17(8):513-519.
[8] 范少泷,邹玉环,房芳,等.甲磺酸阿帕替尼治疗驱动基因未明的晚期非小细胞肺癌的观察性研究[J].中国医药导刊,2017,19(11):1150-1154.
[9] BESSE B.2nd ESMO consensus conference on lung cancer:non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease[J].Ann Oncol,2014,25(8):1475-1484.
[10] DING L,LI Q J,YOU K Y,et al.The use of apatinib in treating nonsmall-cell lung cancer:case report and review of literature[J].Medicine,2016,95(20):e3598.
[11] LANGER C J,MOK T,POSTMUS P E.Targeted agents in the third-/fourth-line treatment of patients with advanced (stage Ⅲ/Ⅳ) non-small cell lung cancer (NSCLC)[J].Cancer Treat Rev,2013,39(3):252-260.
[12] PENG S,ZHANG Y,PENG H,et al.Intracellular autocrine VEGF signaling promotes EBDC cell proliferation,which can be inhibited by apatinib[J].Cancer Lett,2016,373(2):193-202.
[13] LIN C,WANG S S,XIE W W.et al.Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway[J].Oncotarget,2016,7(37):59236-59244.
[14] LI J,QIN S,XU J,et al.Randomized,double-blind,placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J].J Clin Oncol,2016,34(13):1448-1454.
[15] ROVIELLO G,PLOLOM K,ROVIELLO F,et al.Targeting VEGFR-2 in metastatic gastric cancer:results from a literature-based meta-analysis[J].Cancer Invest,2017,35(3):187-194.
[16] EMIL T V,HAJ M N,et al.Second-and third-line systemic therapy in patients with advanced esophagogastric cancer:a systematic review of the literature[J].CancerMetast Rev,2016,35(3):439-456.
[17] HU T,LIU C,LI Q,et al.Apatinib+CPT-11+S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer:case report and literature review[J].Medicine,2018,97(15):349-353.
[18] SCOTT A J,MESSERSMITH W A,JIMENO A.Apatinib:a promising oral antiangiogenic agent in the treatment of multiple solid tumors[J].Drugs Today,2015,51(4):223-232.
[19] HU X,ZHANG J,XU B,et al.Multicenter phase Ⅱ study of apatinib,a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer[J].breast,2014,135(8):1961-1969.
[20] ZHANG L,SHI M Q,HUANG C,et al.A phase Ⅱ,multicenter,placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens[J].J Clin Oncol,2012,30(S15):7548.
[21] LI J,QIN S,XU J,et al.Apatinib for chemotherapy-refractory advanced metastatic gastric cancer:results from a randomized,placebo-controlled,parallel-arm,phase Ⅱ trial[J].J Clin Oncol,2013,31(26):3219-3225.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 382122 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541